Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid

International Journal of Molecular Medicine

Volumn 22, Issue 3, 2008, Pages 293-299

  Jones, Jon ^a   Bentas, Wassilios ^a   Blaheta, Roman A ^a   Makarevic, Jasmina ^a   Hudak, Lukasz ^a   Wedel, Steffen ^a   Probst, Michael ^a   Jonas, Dietger ^a   Juengel, Eva ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Colon cancer; Histone deacetylase; Integrins; Pancreatic cancer; Valproic acid

Indexed keywords

BETA1 INTEGRIN; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; VALPROIC ACID; ENZYME INHIBITOR; HISTONE DEACETYLASE; INTEGRIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ADHESION; CELL ASSAY; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; CELL CULTURE; CELL PROLIFERATION; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY;

CELL ADHESION; CELL PROLIFERATION; CELLS, CULTURED; COLONIC NEOPLASMS; DOWN-REGULATION; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; INTEGRINS; PANCREATIC NEOPLASMS; RNA, MESSENGER; VALPROIC ACID;

EID: 53049101346     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm_00000022     Document Type: Article

References (27)

1. Cinatl J Jr, Cinatl J, Scholz M, Driever PH, Henrich D Kabickova H, Vogel JU, Doerr HW and Kornhuber B: Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs 7: 766-773, 1996.
2. Blaheta RA, Michaelis M, Driever PH and Cinatl J Jr: Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 25: 383-397, 2005.
3. Munster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D and Daud A: Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 25: 1979-1985, 2007.
4. Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, Schwarz SE, Hovelmann S, Gottlicher M, Knuth A and Jager E: Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 97: 177-182, 2007.
5. Guo W and Giancotti FG: Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5: 816-826, 2004.
6. Bülow R, Fitzner B, Sparmann G, Emmrich J, Liebe S and Jaster R: Antifibrogenic effects of histone deacetylase inhibitors on pancreatic stellate cells. Biochem Pharmacol 74: 1747-1757, 2007.
7. Bachem MG, Schünemann M, Ramadani M, Siech M, Beger H, Buck A, Zhou S, Schmid-Kotsas A and Adler G: Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128: 907-921, 2005.
8. Donadelli M, Costanzo C, Beghelli S, Scupoli MT, Dandrea M, Bonora A, Piacentini P, Budillon A, Caraglia M, Scarpa A and Palmieri M: Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 1773: 1095-1106, 2007.
9. Bai J, Demirjian A, Sui J, Marasco W and Callery MP: Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun 348: 1245-1253, 2006.
10. Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N, Komatsu N, Chumakov A, Imai Y and Koeffler HP: Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 121: 656-665, 2007.
11. Sato N, Ohta T, Kitagawa H, Kayahara M, Ninomiya I, Fushida S, Fujimura T, Nishimura G, Shimizu K and Miwa K: FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol 24: 679-685, 2004.
12. Huang X and Guo B: Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells. Cancer Res 66: 9245-9251, 2006.
13. Friedmann I, Atmaca A, Chow KU, Jäger E and Weidmann E: Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer. J Chemother 18: 415-420, 2006.
14. Zgouras D, Becker U, Loitsch S and Stein J: Modulation of angiogenesis-related protein synthesis by valproic acid. Biochem Biophys Res Commun 316: 693-697, 2004.
15. Isenberg JS, Jia Y, Field L, Ridnour LA, Sparatore A, Del Soldato P, Sowers AL, Yeh GC, Moody TW, Wink DA, Ramchandran R and Roberts DD: Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid. Br J Pharmacol 151: 63-72, 2007.
16. Blaheta RA, Michaelis M, Natsheh I, Hasenberg C, Weich E, Relja B, Jonas D, Doerr HW and Cinatl J Jr: Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Cancer 96: 1699-1706, 2007.
17. Beecken WD, Engl T, Ogbonio H, Relja B, Cinatl J, Bereiter-Hahn J, Oppermann E, Jonas D and Blaheta RA: Valproic acid modulates NCAM polysialylation and polysialyltransferase mRNA expression in human tumor cells. Int Inummopharmacol 5: 757-769, 2005.
18. Xia Q, Sung J, Chowdhury W, Chen CL, Hoti N, Shabbeer S, Carducci M and Rodriguez R: Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 66: 7237-7244, 2006.
19. Grzesiak JJ and Bouvet M: Activation of the alpha(2)beta(1) integrin-mediated malignant phenotype on type I collagen in pancreatic cancer cells by shifts in the concentrations of extracellular Mg(2+) and Ca(2+). Int J Cancer 122: 2199-2209, 2008.
20. Kren A, Baeriswyl V, Lehembre F, Wunderlin C, Strittmatter K, Antoniadis H, Fässler R, Cavallaro U and Christofori G: Increased tumor cell dissemination and cellular senescence in the absence of beta1-integrin function. EMBO J 26: 2832-2842, 2007.
21. Shi X, Ma YQ, Tu Y, Chen K, Wu S, Fukuda K, Qin J, Plow EF and Wu C: The MIG-2/integrin interaction strengthens cell-matrix adhesion and modulates cell motility. J Biol Chem 282: 20455-20466, 2007.
22. Winterwood NE, Varzavand A, Meland MN, Ashman LK and Stipp CS: A critical role for tetraspanin CD151 in alpha3beta1 and alpha6beta4 integrin-dependent tumor cell functions on laminin-5. Mol Biol Cell 17: 2707-2721, 2006.
23. Walmod PS, Skladchikova G, Kawa A, Berezin V and Bock E: Antiepileptic teratogen valproic acid (VPA) modulates organisation and dynamics of the actin cytoskeleton. Cell Motil Cytoskeleton 42: 241-255, 1999.
24. Oertl A, Relja B, Makarevic J, Weich E, Höfler S, Jones J, Jonas D, Bratzke H, Baer PC and Blaheta RA: Altered expression of beta1 integrins in renal carcinoma cell lines exposed to the differentiation inducer valproic acid. Int J Mol Med 18: 347-354, 2006.
25. Lin KT, Yeh SH, Chen DS, Chen PJ and Jou YS: Epigenetic activation of alpha4, beta2 and beta6 integrins involved in cell migration in trichostatin A-treated Hep3B cells. J Biomed Sci 12: 803-813, 2005.
26. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E and Herrera LA: Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008 Jan. 15 (Epub ahead of print).
27. Klein G, Langegger M, Timpl R and Ekblom P: Role of laminin A chain in the development of epithelial cell polarity. Cell 55: 331-341, 1988.